(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
03 August 2023 (03.08.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/144684 A1

(51) International Patent Classification:
A61K 31/519 (2006.01) *A61K 47/12* (2006.01)
A61P 35/00 (2006.01) *A61K 47/26* (2006.01)
A61K 9/00 (2006.01)

(21) International Application Number:
PCT/IB2023/050559

(22) International Filing Date:
23 January 2023 (23.01.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202211004186 25 January 2022 (25.01.2022) IN

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) Inventors: **CHAVDA, Alpakumari**; Novartis Healthcare Private Limited, Plot no. 4, Survey no's 101 and 101/2, Lalgadi Malakpet, Shameerpet Hyderabad 500101 (IN). **CHERKUPALLY, Laxman**; Novartis Healthcare Private Limited, Plot no. 4, Survey no's 101 and 101/2, Lalgadi Malakpet, Shameerpet Hyderabad 500101 (IN). **DUBEY, Vivek**; Novartis Healthcare Private Limited, Plot no. 4, Survey no's 101 and 101/2, Lalgadi Malakpet, Shameerpet Hyderabad 500101 (IN). **TARIQ, Muzammil**; Novartis Healthcare Private Limited, Plot no. 4, Survey no's 101 and 101/2, Lalgadi Malakpet, Shameerpet Hyderabad 500101 (IN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

WO 2023/144684 A1

(54) Title: RIBOCICLIB PHARMACEUTICAL COMPOSITIONS

(57) Abstract: Disclosed are pharmaceutical formulations containing 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide succinate, methods of using said formulations in therapy and processes for preparing the same.